Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 1999

View Archived Issues

Sumitomo applies for approval of amrubicin

Soltec enters strategic alliance with Mipharm

Dynal to provide component for Xcyte Therapies' activated T-cell product

NexMed initiates phase II trials of alprostadil cream in U.S.

Two new patents issued to Helix for drug delivery technology

Oxo Chemie reports promising data for immune therapeutic

Licensing opportunity from NIH: glycoprotein hormone superagonists

Allelix/NPS merger approved by stockholders, Canadian court

Vasomax progress updated by Zonagen

Pivotal studies begin for Emitasol

Statins as new approach to the treatment of bone loss diseases

Dexmedetomidine receives FDA marketing approval

Novartis discloses several new compounds for proliferative, inflammatory conditions

FDA is first agency worldwide to approve new fluoroquinolone for marketing

Cytotoxic polyheterocyclic compounds designed at Taiwan research institute

Meiji Seika presents heterocyclic inhibitors of platelet aggregation

New agents for diabetes in development at Otsuka

Pretreatment with complement inhibitor significantly reduces cardiac, brain damage following CPB

Selective, orally active factor Xa inhibitors designed by JT scientists

New FTase inhibitors from Schering-Plough with good cellular activity

MJ-355: a new K(ATP) channel opener with antihypertensive and cardioprotective effects

Scandipharm to become wholly owned subsidiary of Axcan

Acute and chronic effects of two new TZDs on glucose metabolism examined in rats

New agent for treating cocaine dependency in development at RBI

Major regulatory filings made for unique antidiabetic medication

Isis surprised by disappointing results in Crohn's disease study of ISIS-2302

Simultaneous E.U. and U.S. submissions for Combidex, a new MRI contrast agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...